Ovarian cancer has been one of the most malignant cancers in women, with the incidence increasing year by year. The most universally used preclinical models, cancer cell lines, and mouse models have many drawbacks making them fundamentally limited in representing the real characteristics of cancer. Numerous anticancer drugs developed from screening cancer cell lines and mouse models have failed in clinical trials. Organoids have been the focus of significant research in recent years, they can replicate the biological features of the parental tumor, and predict individual patient’s response to anticancer drugs. Organoids provide a new in vitro model for basic research and clinical treatment of cancer. In this review, we will focus on the latest progress in the establishment of ovarian cancer organoids and their application for anticancer drug screening.
HomeArticlesVol 31,2021 No.4Detail
Progress in the development of ovarian cancer organoids and their application in drug testing
Published on Aug. 25, 2021Total Views: 3365 timesTotal Downloads: 2058 timesDownloadMobile
- Abstract
- Full-text
- References
Abstract
Full-text
References
1.Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer[J]. CA Cancer J Clin, 2011, 61(3): 183-203. DOI: 10.3322/caac.20113.
2.Timmermans M, Sonke GS, van de Vijver KK, et al. No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands[J]. Eur J Cancer, 2018, 88: 31-37. DOI: 10.1016/j.ejca.2017.10.030.
3.Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles[J]. Nat Commun, 2013, 4: 2126. DOI: 10.1038/ncomms3126.
4.Bleijs M, van de Wetering M, Clevers H, et al. Xenograft and organoid model systems in cancer research[J]. EMBO J, 2019, 38(15): e101654. DOI: 10.15252/embj.2019101654.
5.Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer[J]. Cell, 2018, 173(2): 515-528. DOI: 10.1016/j.cell. 2018.03.017.
6.Yan HH, Siu HC, Law S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening[J]. Cell Stem Cell, 2018, 23(6): 882-897. DOI: 10.1016/j.stem. 2018.09.016.
7.Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer[J]. Cell, 2014, 159(1): 176-187. DOI: 10.1016/j.cell.2014.08.016.
8.Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer[J]. Cell, 2015, 160(1-2): 324-338. DOI: 10.1016/j.cell.2014.12.021.
9.Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening[J]. Nat Med, 2017, 23(12): 1424-1435. DOI: 10.1038/nm.4438.
10.Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018, 172(1-2): 373-386. DOI: 10.1016/j.cell.2017. 11.010.
11.Boretto M, Maenhoudt N, Luo X, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening[J]. Nat Cell Biol, 2019, 21(8): 1041-1051. DOI: 10.1038/s41556-019-0360-z.
12.Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium[J]. Gastroenterology, 2011, 141(5): 1762-1772. DOI: 10.1053/j.gastro.2011.07.050.
13.Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J]. Nature, 2009, 459(7244): 262-265. DOI: 10.1038/nature07935.
14.Hill SJ, Decker B, Roberts EA, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids[J]. Cancer Discov, 2018, 8(11): 1404-1421. DOI: 10.1158/2159-8290.CD-18-0474.
15.Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity[J]. Nat Med, 2019, 25(5): 838-849. DOI: 10.1038/s41591-019-0422-6.
16.Maenhoudt N, Defraye C, Boretto M, et al. Developing organoids from ovarian cancer as experimental and preclinical models[J]. Stem Cell Rep, 2020, 14(4): 717-729. DOI: 10.1016/j.stemcr.2020.03.004.
17.Hoffmann K, Berger H, Kulbe H, et al. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment[J]. EMBO J, 2020, 39(6): e104013. DOI: 10.15252/embj.2019104013.
18.Nanki Y, Chiyoda T, Hirasawa A, et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing[J]. Sci Rep, 2020, 10(1): 12581. DOI: 10.1038/s41598-020-69488-9.
19.de Witte CJ, Espejo Valle-Inclan J, Hami N, et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses[J]. Cell Rep, 2020, 31(11): 107762. DOI: 10. 1016/j.celrep.2020.107762.
20.Mcgranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628. DOI: 10.1016/j.cell.2017.01.018.
21.Maru Y, Tanaka N, Itami M, et al. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors[J]. Gynecol Oncol, 2019, 154(1): 189-198. DOI: 10.1016/j.ygyno.2019.05.005.
22.Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment[J]. Am J Transl Res, 2014, 6(2): 114-118. DOI: 10.2147/OTT.S64230.
23.Horvath P,Aulner N,Bickle M,et al. Screening out irrelevant cell-based models of disease[J]. Nat Rev Drug Discov, 2016, 15(11): 751-769. DOI: 10.1038/nrd.2016. 175.
24.Chen H, Gotimer K, de Souza C, et al. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma[J]. Gynecol Oncol, 2020, 157(3): 783-792. DOI: 10.1016/j.ygyno.2020.03.026.
Popular Papers
-
Establishment of predictive model for cardiovascular complication of diabetes mellitus
Jan. 31, 2024897
-
Research progress on the mechanism of long non-coding RNA LINC00641 in the development of malignant tumors
Jan. 31, 2024653
-
Research on the promotion of clinical practice guidelines implementation (Ⅶ): comparison and analysis of terminology system in clinical practice guidelines based on ontology
Jan. 04, 2024614
-
Research on evidence-based social intervention guidelines and standards Ⅰ: developing standards based on evidence-based concepts
Jan. 31, 2024531
-
Influence of parental care burden on quality of life of school-age children with asthma: mediating role of coping style
Dec. 25, 2023427
-
Construction of the risk predition model of mild cognitive impairment in hospitalized elder patients
Jan. 31, 2024425
-
Reliability and validation of Chinese version of Online Social Support Scale for older adults
Jan. 31, 2024421
-
Effects of screen time and internet addiction on social anxiety among adolescents in a district of Chongqing
Dec. 25, 2023415